REGENXBIO Reports Fourth Quarter and Full-Year 2019 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Regenxbio (RGNX) Misses Q4 EPS by 28c, Revenues Miss
February 26, 2020 4:44 PM ESTRegenxbio (NASDAQ: RGNX) reported Q4 EPS of ($0.72), $0.28 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $11.77 million versus the consensus estimate of $39.67 million.
Additional data from RGX-314 Phase I/IIa trial for wet AMD expected in 1H 2020RGX-314 clinical trials for treatment of wet AMD and diabetic retinopathy expected to advance in 2020 using subretinal and suprachoroidal delivery... More